On the basis of the newer literature evidence, the U.S. Food and Drug Administration (FDA) recently revised the Emergency Use Authorization (EUA) of COVID-19 CP, authorizing its use at high titer for the treatment of hospitalized COVID-19 patients early in the course of disease and those hospitalized with impaired humoral immunity [29]. The gene discussed is CP; the disease is COVID-19.